Latest IR information
IR News
- 2026.03.17
- SymBio Achieves First Patient In (FPI) in Global Phase 3 Clinical Trial of IV BCV for Adenovirus Infection Following Hematopoietic Stem Cell Transplantation
- 2026.03.16
- SymBio Secures Japan Patent for Use of IV BCV in Malignant Lymphoma — Accelerating Expansion into Oncology —
- 2026.03.02
- Notice Regarding the Monthly Exercise Status of the 58th Stock Acquisition Rights Issued through Third-Party Allotment
- 2026.02.27
- Notice of Convocation of the 21st Ordinary General Meeting of Shareholders
- 2026.02.27
- Other Matters Subject to Measures for Electronic Provision for the 21st Annual Shareholders’ Meeting (Matters Omitted from the Delivered Documents)